sparse_primary_supporting_bucket
Central evidence is high but primary supporting bucket is empty. Classification tiers may still be too coarse.
fulltoplow inflation risk
Faecalibacterium prausnitzii
crohn's disease
Faecalibacterium prausnitzii appears to be a strong and relatively human-grounded signal in crohn's disease.
Faecalibacterium prausnitzii shows a strong literature footprint in crohn's disease, with substantial central evidence and broader supporting literature.
faecalibacterium_prausnitzii
Credibility score
88
Human translation
4/5
Reproducibility
5/5
Novelty
1/5
Actionability
5/5
Credibility 88Human translation 4/5Reproducibility 5/5Novelty 1/5Actionability 5/5
Why this scores the way it does
- strong central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- directionality and confounding still require curated review
Internal review flags
1 flagsPrimary central evidence
27 papersBacterial flora in inflammatory bowel disease.
2009Digestive diseases (Basel, Switzerland)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Faecalibacterium prausnitzii and Crohn's disease - is there any connection?
2013Polish journal of microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
2014Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis.
2016The Journal of allergy and clinical immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Assessing intestinal permeability in Crohn's disease patients using orally administered 52Cr-EDTA.
2019PloS one
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Faecalibacterium prausnitzii produces butyrate to decrease c-Myc-related metabolism and Th17 differentiation by inhibiting histone deacetylase 3.
2019International immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.
2020Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3.
2020Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota changes in inflammatory bowel diseases and ankylosing spondilytis.
2021Journal of gastrointestinal and liver diseases : JGLD
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn's disease: A randomized controlled trial.
2022EClinicalMedicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Human CD4+CD8α+ Tregs induced by Faecalibacterium prausnitzii protect against intestinal inflammation.
2022JCI insight
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Faecalibacterium prausnitzii Ameliorates Colorectal Tumorigenesis and Suppresses Proliferation of HCT116 Colorectal Cancer Cells.
2022Biomedicines
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Location-specific signatures of Crohn's disease at a multi-omics scale.
2022Microbiome
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Immunomagnetic Capture of Faecalibacterium prausnitzii Selectively Modifies the Fecal Microbiota and Its Immunomodulatory Profile.
2023Microbiology spectrum
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Comparative diet-gut microbiome analysis in Crohn's disease and Hidradenitis suppurativa.
2023Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota signatures in inflammatory bowel disease.
2024United European gastroenterology journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial Disruptions in Inflammatory Bowel Disease: A Comparative Analysis.
2024International journal of general medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.
2024Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Metaproteomics reveals diet-induced changes in gut microbiome function according to Crohn's disease location.
2024Microbiome
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota and blood biomarkers in IBD-Related arthritis: insights from mendelian randomization.
2025Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn's disease.
2025Cell metabolism
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota transplantation restores gut microbiota diversity in children with active Crohn's disease: a prospective trial.
2025Journal of translational medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Faecalibacterium Diversity in the Gut Microbiome of Crohn's Disease Patients.
2025United European gastroenterology journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Faecalibacterium Prausnitzii extracellular vesicles regulating macrophage differentiation via homologous recombination repair in colitis model.
2025Microbiological research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.
2025Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Single cell viral tagging of Faecalibacterium prausnitzii reveals rare bacteriophages omitted by other techniques.
2025Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Uncovering the Dynamics of Mucosa-Associated Microbiota in Postoperative Recurrence of Crohn's Disease.
2026Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
13 papersFaecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.
2008Proceedings of the National Academy of Sciences of the United States of America
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.
2016Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression.
2020Journal of diabetes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii Attenuates DSS-Induced Colitis by Inhibiting the Colonization and Pathogenicity of Candida albicans.
2021Molecular nutrition & food research
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Human gut microbiota-reactive DP8α regulatory T cells, signature and related emerging functions.
2022Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut Microbiome Composition Is Associated With Future Onset of Crohn's Disease in Healthy First-Degree Relatives.
2023Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity.
2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii served as key components of fecal microbiota transplantation to alleviate colitis.
2024American journal of physiology. Gastrointestinal and liver physiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii-derived extracellular vesicles alleviate chronic colitis-related intestinal fibrosis by macrophage metabolic reprogramming.
2024Pharmacological research
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbial and metabolomics profiles reveal the potential mechanism of fecal microbiota transplantation in modulating the progression of colitis-associated colorectal cancer in mice.
2024Journal of translational medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii Ameliorates DSS-Induced Colitis via Modulating Bile Acid Metabolism and Regulating FXR Signaling.
2025Digestive diseases and sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Microbial Anti-Inflammatory Molecule (MAM) secreted by Faecalibacterium prausnitzii ameliorates colitis through autophagy and gut microbiota modulation.
2025Journal of translational medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes.
2026Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
19 papersThe microbiota in inflammatory bowel disease in different age groups.
2009Digestive diseases (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature.
2014Gastroenterology research and practice
Relevant review or meta-analysis for the signal-disease area.
The intestinal microbiome in spondyloarthritis.
2015Current opinion in rheumatology
Relevant review or meta-analysis for the signal-disease area.
Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut.
2016Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics.
2017The ISME journal
Relevant review or meta-analysis for the signal-disease area.
Impact of Omega-3 Fatty Acids on the Gut Microbiota.
2017International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Emergent Behavior of IBD-Associated Escherichia coli During Disease.
2019Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Bacterial Dysbiosis and Translocation in Psoriasis Vulgaris.
2019Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review.
2020Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease.
2021Journal of gastroenterology and hepatology
Relevant review or meta-analysis for the signal-disease area.
The Modification of the Gut Microbiota via Selected Specific Diets in Patients with Crohn's Disease.
2021Nutrients
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease.
2021Frontiers in nutrition
Relevant review or meta-analysis for the signal-disease area.
Alteration of the Gut Microbiome in Inflammatory Bowel Disease.
2023Digestion
Relevant review or meta-analysis for the signal-disease area.
Anaerobes in specific infectious and noninfectious diseases: new developments.
2023Anaerobe
Relevant review or meta-analysis for the signal-disease area.
Faecalibacterium: a bacterial genus with promising human health applications.
2023FEMS microbiology reviews
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
2024Microbiological research
Relevant review or meta-analysis for the signal-disease area.
Healing from Within: How Gut Microbiota Predicts IBD Treatment Success-A Systematic Review.
2024International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota mediated T cells regulation and autoimmune diseases.
2024Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).
2025International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.